Daily Morning Note – 16 April 2021


Asian stocks look poised to gain after surprisingly robust economic data helped propel U.S. benchmark indexes to records. Yields on benchmark 10-year Treasury notes declined. The S&P 500 Index’s advance was led by real estate and health care, while rallies in technology shares also lifted the Nasdaq 100. Wall Street stocks shot to fresh records on Thursday (April 15) following blowout earnings from large banks and strong US economic data showed the recovery picking up speed. The Dow Jones Industrial Average climbed 0.9 per cent to a record 34,035.99, and the first close above 34,000. The broad-based S&P 500 also ended at a record, gaining 1.1 per cent to 4,170.42, while the tech-rich Nasdaq Composite Index jumped 1.3 per cent to finish at 14,038.76. The records came as Citigroup and Bank of America joined the parade of large banks reporting at least a doubling of quarterly profits on strong trading results and large reserve releases amid the improving economic outlook.

Elsewhere, China is expected to report the highest quarterly economic growth ever since it began releasing such data 30 years ago. But investors will need to look beyond that number to assess the state of the Chinese economy’s post-pandemic recovery. Bitcoin gained and Coinbase fell despite news that three funds at Cathie Wood’s Ark Investment Management bought shares at Wednesday’s debut of the largest digital asset exchange. Oil extended gains from Wednesday’s surge.


SG News

Singapore Medical Group (SMG) announced that a potential transaction involving its company’s shares will not be explored further, according to an exchange filing on Thursday. In December last year, the group said that it was in preliminary discussions with a third party regarding a transaction involving SMG’s shares. This was shared in response to a query from its sponsor CIMB Bank Singapore regarding “unusual price movements” and the significant volume of trading in the shares. In the filing, SMG said that it remains open to exploring various avenues to improve shareholder value, including corporate actions.

Mainboard-listed Gallant Venture on Thursday morning gave notice of recording three consecutive years of pre-tax losses, based on its audited full-year consolidated accounts. Gallant Venture, a developer, master planner and manager for industrial parks and resorts in Batam and Bintan, said its six-month average daily market capitalisation as at April 14 was S$709.8 million. This means it still meets the financial entry criteria to avoid being placed on the Singapore Exchange’s (SGX) watch list. Firms are placed on the SGX watch list if they record losses for the three latest consecutive financial years and have an average daily market cap of under S$40 million over the last six months.

ERA Realty eyes 40% increase in revenue amid boom in property transactions. Target amount is S$550 million by early next year, in line with its 40th anniversary; goal this year is S$450 million. ERA Realty Network is on a roll, as it rides the momentum of the nation’s gangbuster residential market. The company, Singapore’s second largest real estate agency is gunning for 40 per cent increase in revenue to S$550 million by early next year, in line with its 40th anniversary, senior executives said in an exclusive interview with The Business Times.

New private home sales in S’pore hit 4-year high for March as buyers flocked to high-end condos. An estimated 3,574 new private homes were sold in the January-March of this year. Buyers jumped in after the Chinese New Year break in anticipation of an economic recovery, sending new private home sales last month to 1,296 units – the highest March take-up since 2017 and double the 645 units sold in February. Year on year, developers booked 96 per cent more sales in March, with a little under half of the units coming from high-end condominiums in the prime districts. “Buyers flush with cash and seeking stability are investing in stable assets like properties,” said Mr Lee Sze Teck, director of research at Huttons Asia. An estimated 3,574 new private homes were sold in the January to March period this year – the highest quarterly sales since the second quarter of 2013 when 4,538 units were taken up, he added. Developers launched 959 units for sale in March, up from 167 in February, but down from 2,600 in January. Year on year, they launched nearly 66 per cent more units.

Singapore exports blow past forecast, jumping 12.1% on low base, chip crunch in March. Singapore’s key exports extended gains in March for the fourth straight month, helped by non-electronics shipment growth and a low base for electronics. Non-oil domestic exports (NODX) surged by 12.1 per cent year on year, a pickup from the growth of 4.2 per cent in the month before. The expansion, announced on Friday by trade agency Enterprise Singapore (ESG), handily beat the median rise of 2.6 per cent estimated by private-sector analysts in a Bloomberg poll. Electronic NODX grew by 24.4 per cent, compared with 7.3 per cent in February, and lifted by a year-ago trough in March 2020. The latest performance was driven by a 19 per cent jump in integrated circuits, with ESG citing reports of global chip shortages worldwide.

US News

The Federal Reserve is seeing both labour and material shortages mounting up across several sectors of the US economy, which may have consumers paying even more for everything from fuel to new homes. In the Fed’s Beige Book report released on Wednesday (April 14), the central bank references “shortage” or “shortages” 37 times, up six mentions from a previous decade-high total in March. That’s also 12 times more than the same period in 2020, during the early days of the Covid-19 pandemic. Shortages have been a persistent economic theme since the early days of the outbreak, when store shelves were completely emptied of lockdown necessities such as toilet paper, hand sanitiser and personal protective equipment. More than a year after the pandemic’s onset, scarcity concerns are primarily focused around global supply-chain issues and strengthening demand in the rebounding economy.

Bank of America reported a jump in first-quarter profit that breezed past estimates on Thursday as it released reserves it had set aside to cover potential coronavirus loan losses. The bank released US$2.7 billion from its reserves, betting on a swift economic recovery as more people get vaccinated and businesses return to normal. The second-largest US bank by assets also reported a 12 per cent fall in consumer banking revenue to US$8.1 billion in the quarter ended March. Appetite for new loans waned during the pandemic as customers spent less and saved more and large companies relied on capital markets for funds rather than their bank.

Citigroup on Thursday posted results that beat analysts’ estimates for first-quarter profit with strong investment banking revenue and a bigger-than-expected release of loan-loss reserves. The firm also said it was shuttering retail banking operations in 13 countries across Asia and parts of Europe to focus more on wealth management outside the U.S., one of the first big strategic moves made by CEO Jane Fraser, who took over in February. The bank said it was exiting consumer operations in Australia, Bahrain, China, India, Indonesia, Korea, Malaysia, the Philippines, Poland, Russia, Taiwan, Thailand and Vietnam. The firm will focus its non U.S. consumer banking operations on Singapore, Hong Kong, the UAE and London, the bank said.

Thermo Fisher Scientific has agreed to acquire PPD a provider of clinical and research services to the pharma and biotech industries, for US$17.4 billion as health-care dealmaking soars amid the pandemic. Thermo Fisher will pay US$47.50 a share for PPD, according to a statement on Thursday, and will assume about US$3.5 billion of debt. The price represents a premium of about 24 per cent to the PPD closing price Tuesday, before reports of a possible deal. The drug-testing field has become a hotbed of activity as the pandemic runs into its second year. Companies around the world are seeking to roll out new Covid-19 drugs and vaccines, even as they continue with their more standard business lines of developing new cancer therapies and other treatments. Health-care dealmaking has also been on a tear, with companies announcing more than US$160 billion of transactions this year – almost three times the volume in the same period of 2020. In February, Icon agreed to acquire PRA Health Sciences in a contract-research deal valued at about US$12 billion.

Coinbase stock closes down day after landmark Nasdaq debut. Coinbase shares whipsawed Thursday, a day after the cryptocurrency exchange went public in a blockbuster direct listing. The firm’s stock closed down 1.68%, though had climbed as high as 6.4% in the morning. The company said that it temporarily disabled withdrawals of ether tokens due to an issue with a recent upgrade to that currency’s network. The so-called “Berlin hard fork” is part of a broader effort to make the Ethereum blockchain faster and more secure.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR


Jardine Cycle & Carriage Ltd

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

Jardine C&C Ltd (SGX: C07) technical indicate a bullish revival after the stock has range bound for a year
Buy limit: 22.82 Stop loss: 20.76 Take profit 1: 26.55 Take profit 2: 28.06

>> Read more Technical reports

HK Reports – Read up on our Hong Kong reports here

Webinar Of The Week

Market Outlook: IX Biopharma Ltd, SG REITs Monthly, SG Weekly – Week 15

Date: 12 April 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 – Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information

The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.


Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you


This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  


Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com